A Danish start-up, BioPhenyx, has developed a functional genetic assay that uses CRISPR to evaluate the effects of any mutation of interest. The...

In this week's clinical update, we look at recent news from Caribou Biosciences. The company's second gene-edited CAR-T cell therapy candidate,...

Founded in 2011, Caribou Biosciences is developing novel allogeneic CAR-T cell and CAR-natural killer cell therapies to treat cancer. The UC Berkeley...

This week’s update looks at a Phase 1/2 study for ALLO-501A, a TALEN-edited CAR T-cell therapy for large B-cell lymphoma.

Last week, Allogene Therapeutics announced the publication of data from the Phase 1 UNIVERSAL trial of ALLO-715, a TALEN-engineered CAR-T candidate...

In this clinical update, we look at four ongoing clinical trials involving a gene-edited therapeutic candidate for the treatment of solid cancers.

In this post, we introduce our CMN disease overview, which will provide information on all the diseases that are targeted by gene-editing therapies...